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Epidermal growth factor receptor (EGFR) mutation status has
been shown to predict response to anti-EGFR tyrosine kinase
inhibitors in non-small cell lung cancer (NSCLC). In patients
with advanced-stage NSCLC, evaluation of mutational status is
increasingly requested on biopsy or fine-needle aspiration speci-
mens, which often have limited material. There are limited data
on the suitability of cytology cell blocks (CB) for EGFR muta-
tion testing. In this study, we report our institutional experience
with cytology cell block material for EGFR mutation testing. We
retrospectively reviewed EGFR mutation analyses performed on
234 surgical (SP) and cytology (CB) from October 2007 to May
2010. One hundred ninety-two SP specimens and 42 CB speci-
mens were evaluated for EGFR mutation. CB specimens were
evaluated for overall specimen size based on aggregate cellular-
ity in comparison to small biopsy specimens, and percent tumor.
Of the 192 SP and 42 CB specimens, 31 (16.1%) and 11
(26.2%) were positive for EGFR mutation, respectively; there
does not appear to be an association between mutation detection
rate and the source of the specimen (P ¼ 0.124). Limited DNA
was obtained from 70.0% (29/42), including 81.8% (9/11) of
those which were mutation positive. Additionally, 45.4% (5/11)
of mutation positive specimens had extremely low DNA yields.
Although 16.6% (7/42) of CB specimens had <10% tumor, all
11 mutation positive CB cases had >10% tumor. These data
indicate that CB specimens provide an alternative source for
molecular evaluation of NSCLC, and that tumor percentage may
be more important than specimen size and/or DNA yield in
determining the suitability of these specimens for testing. Diagn.
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Lung cancer is the most frequent cause of cancer-related
death, with an estimated mortality of 1.4 million deaths
annually worldwide.1 Despite the high burden of this dis-
ease and extensive ongoing research, the median survival
for patients with lung cancer remains low, with 5 year rel-
ative survival rates averaging just above 15%.2
In the last decade, it has become evident that aberra-
tions of the epidermal growth factor receptor (EGFR) sig-
naling pathway are a common event in non-small cell
lung cancer (NSCLC).3 Activating mutations in EGFR
(ERBB1, HER1) are seen in a significant subset of
patients with NSCLC, ranging from 10 to 40% of
patients, with increased incidence in adenocarcinoma,
non-smokers, females, and Asians.4 EGFR is a receptor
tyrosine kinase which, upon activation, triggers a down-
stream cascade of growth-promoting signals, and activat-
ing mutations in EGFR are thought play a key role in the
molecular pathogenesis of NSCLC.5 The elucidation of
the role of activating EGFR mutations in NSCLC carries
a significant clinical import, as treatment with the EGFR
tyrosine kinase inhibitors gefitinib and erlotinib have been
shown to prolong progression free survival in patients
harboring an activating mutation.6 These findings have
led to the recommendation to use EGFR tyrosine kinase
inhibitors as first-line therapy in patients with advanced
stage disease harboring an activating mutation in EGFR.7
The evaluation of EGFR mutation status in patients with
advanced stage NSCLC has increasingly moved into rou-
tine clinical practice, and is considered by some to be a
new standard of care.8 However, a logistical predicament
occurs in this setting, as patients with advanced stage
NSCLC are not considered surgical candidates, and thus
there is frequently limited lesional tissue on which to
perform EGFR mutation analysis. The majority of patients
with NSCLC presents with advanced stage disease2,9 and
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do not undergo surgical resection; therefore this problem
carries broad implications in the widespread implementa-
tion of molecular characterization prior to targeted therapy.
At present a common modality for the diagnosis of
NSCLC is through evaluation of cytologic specimens
(fine-needle aspiration (FNA), pleural fluids, and bron-
chial washing and brushings). Therefore, it is of crucial
clinical importance to understand whether small samples,
such as cytology specimens, are adequate for mutational
analysis of tumors. Previous studies have examined the
suitability of small specimens for EGFR mutational analy-
sis using a variety of approaches and have demonstrated
that preparations from cytology material are appropriate
for testing.10 Here, we report our institutional experience
at the University of Pennsylvania in evaluating and utiliz-
ing cell block preparations of routine cytology material
for directed mutational analysis of EGFR for therapeutic
decision-making in patients with NSCLC.
Methods
Patient Specimens
We retrospectively reviewed a cohort of 234 consecutive
specimens with NSCLC on which EGFR mutation testing
was performed clinically between October 2007 and May
2010 with appropriate institutional approval (IRB protocol
810602). One hundred ninety-two (192) specimens were
surgical pathology (SP) specimens, consisting of either bi-
opsy or resection material, and 42 specimens were cytol-
ogy cell blocks (CB). Cytology CB were chosen for test-
ing for mutational analysis of EGFR mutation when no
other specimen was available, or paired biopsy material
was deemed to be inadequate due to no or low tumor con-
tent. The cytology cell block specimens included FNA of
primary lung lesions, FNA of metastatic lesions, and
exfoliative cytology specimens. The cytology specimens
were processed according to routine cytopathology proce-
dures, with a portion of the material utilized for air-dried
Diff-Quik 1 stained slides, Papanicolaou stained alcohol
fixed smears (the smears were made only in FNA speci-
mens), and the remaining aspirated material was rinsed in
Normosol 1 for cytopsin (made only in cases of exfolia-
tive cytology specimens), ThinPrep1, and cell block prep-
arations and was stored at 48C if not immediately proc-
essed. The CB were prepared within 24 hours of speci-
men receipt by centrifuging the pooled needle rinse at
1800 rpm for 10-min to form a pellet/sediment which was
resuspended in 10 ml of 95% formalin solution. This was
followed by another round of centrifugation at 1800 rpm
for 10 min; the cell button was gently scraped and trans-
ferred to a small filter paper packet for routine paraffin
embedding and evaluation by H&E staining. Immunohis-
tochemical stains for TTF-1 (Mouse monoclonal, 1:50
dilution, Dako, Inc., Carpinteria, CA) were performed as
part of the routine diagnostic evaluation at the discretion
of the cytopathologist. In three cases, a matched pair con-
sisting of resection specimen and FNA specimen was
available for evaluation.
Cytology cell block specimens were retrospectively
reviewed by three pathologists for assessment of tumor
percentage. Tumor percentage was evaluated based on the
number of tumor cells compared to all nucleated cells in
the specimen, and graded by consensus into five catego-
ries of tumor percentage:<5%; >5–10%; >10–25%; >25–
50%; >50%. When available, TTF-1 stain of the cell
block was utilized to confirm the morphologic determina-
tion of the tumor percentage. CB were also assessed for
the number of tumor clusters of at least 10 cells per 310
field (averaged over 5 observed fields in areas of highest
cellular concentration). Cell clusters which were greater
than 10 cells were counted as multiples of 10 clusters as
appropriate (i.e., a cluster of approximately 20 cells
counted as two clusters). Additionally, CB were estimated
for overall size of tissue present based on a visual aggre-
gation of tissue into four categories: scant; >0.5–2 mm2;
2–5 mm2, >5 mm2–1 cm2.
Evaluation of EGFR Mutation Status
Two major types of EGFR mutations, exon 19 in-frame
deletions and p.Leu858Arg (L858R), which account for
approximately 90% of mutations by prevalence, were
evaluated. For SP specimens, formalin-fixed paraffin-em-
bedded tissue was cut into 5 micron sections and man-
ually macrodissected to enrich for areas of tumor based
on areas identified by a surgical pathologist. For cell
block specimens, 10 micron paraffin curls were cut from
the cytology CB, and 6–9 curls of tissue were utilized for
DNA extraction, with the exception of one cytology cell
block specimen, which showed an area with a high con-
centration of tumor cells and was manually macrodis-
sected in a manner analogous to a SP specimen. DNA
from the specimens was extracted by deparaffinization
with xylene followed by proteinase K (Qiagen, Inc.)
digestion in Qiagen ATL buffer overnight at 568C. After
an RNase digestion step, the DNA was extracted using
QIAmp (Qiagen, Inc.) spin columns according to the
manufacturer instructions. Analysis of DNA concentration
was performed using spectrometry. Evaluation for EGFR
mutation status was performed using a polymerase chain
reaction (PCR) approach as previously described.11
Briefly, two separate PCR reactions were performed to
amplify regions of interest in exon 19 and exon 21 using
fluorescently labeled PCR primers. The products of the
exon 19 amplification were directly evaluated for size to
determine whether a fragment of reduced size, represent-
ing a deletion was present. The products of the exon 21
amplification were subjected to restriction endonuclease
digestion with Sau96I, which allows for the detection of
the L858R mutation (NM_005228.3:c.2573T>G) by virtue
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of the fact that this mutation generates a Sau96I restric-
tion site. Amplification and digestion products were sep-
arated by capillary gel electrophoresis on an Applied
Biosystems 3130XL according to the manufacturer’s pro-
tocol. Data analysis was performed with GeneMapper
3.7 software. Interpretive criteria for the presence of
mutation were as previously described. The EGFR muta-
tion assay was determined to have an analytic sensitivity
of *5% based on dilution studies with an input of 25 ng
of DNA.
Statistical Analyses
Statistical analysis was performed using Stata 11 (Stata-
Corp LP, College Station, TX). Comparisons between the
surgical and the cytology specimens were made using the
Table I. Patient Characteristics
All cases Surgical cases Cytology cases
N 234 192 42
Age (years)
Range 25–96 25–96 40–80
Median 64 64 67
Gender
M (%) 88 (38) 75 (39) 13 (31)
F (%) 146 (62) 117 (61) 29 (69)
Smoking status
Never smoker (%) 62 (26.5) 51 (26.6) 11 (26.2)
Ever smoker (%) 155 (66.2) 126 (65.6) 29 (69.0)
Not available (%) 17 (7.2) 15 (7.8) 2 (4.8)
Race
Caucasian 158 (67.5) 122 (63.5) 36 (85.7)
African descent 19 (8.1) 17 (8.9) 2 (4.8)
Asian 3 (1.3) 2 (1.0) 1 (2.4)
Hispanic 1 (0.4) 1 (0.5) 0 (0)
Other 5 (2.1) 5 (2.6) 0 (0)
Not available 48 (20.5) 45 (23.4) 3 (7.1)
Table II. Specimen Characteristics
No. Gender Procedure Type Site Diagnosis
1 F FNA Lung Adenocarcinoma
2 F FNA Lung Adenocarcinoma
3 M Fluid Pleural effusion Adenocarcinoma
4 M EBUS-FNA Lymph node Adenocarcinoma
5 F FNA Bone Adenocarcinoma
6 F Fluid Pleural Effusion Poorly differentiated carcinoma
7 M EBUS-FNA Lymph node Poorly differentiated carcinoma
8 F FNA Bone Adenocarcinoma
9 M FNA Lung Adenocarcinoma
10 F Fluid BAL Adenocarcinoma
11 F EBUS-FNA Lymph node Adenocarcinoma
12 F EBUS-FNA Lymph node Adenocarcinoma
13 F FNA Bone Adenocarcinoma
14 M EBUS-FNA Lung Poorly differentiated carcinoma
15 F Fluid Pleural Effusion Adenocarcinoma
16 F FNA Bone Adenocarcinoma
17 F EBUS-FNA Lymph node Adenocarcinoma
18 F EBUS-FNA Lymph node Poorly differentiated carcinoma
19 F Fluid Pericardial Effusion Poorly differentiated carcinoma
20 F FNA Scapula Adenocarcinoma
21 F Fluid Pleural effusion Non-small cell lung carcinoma,
favor adenocarcinoma
22 F FNA Lung Poorly differentiated carcinoma
23 M EBUS-FNA Lymph node Adenocarcinoma
24 M EBUS-FNA Lung Poorly differentiated carcinoma
25 F EBUS-FNA Mass Non-small cell lung carcinoma,
favor adenocarcinoma
26 F EBUS-FNA Lymph node Adenocarcinoma
27 M Fluid Pleural Poorly differentiated carcinoma
28 F EBUS-FNA Lung Adenocarcinoma
29 F EBUS-FNA Lung Adenocarcinoma
30 F EBUS-FNA Lymph node Adenocarcinoma
31 F EBUS-FNA Lymph node Non-small cell lung carcinoma,
favor squamous
32 M FNA Lung Adenocarcinoma
33 F Fluid Pleural Adenocarcinoma
34 F EBUS-FNA Lymph node Poorly differentiated carcinoma
35 M EBUS-FNA Lymph node Poorly differentiated carcinoma
36 F EBUS-FNA Lymph node Poorly differentiated carcinoma
37 M EBUS-FNA Lymph node Adenocarcinoma
38 F EBUS-FNA Lymph node Poorly differentiated carcinoma
39 M EBUS-FNA Lymph node Poorly differentiated carcinoma
40 F FNA Lung Poorly differentiated carcinoma
41 F FNA Lung Non-small cell lung carcinoma
42 F EBUS-FNA Lymph node Poorly differentiated carcinoma
AISNER ET AL.
318 Diagnostic Cytopathology, Vol 41, No 4
Diagnostic Cytopathology DOI 10.1002/dc
Wilcoxon rank sum test (age) and the chi-square test
(EGFR mutation status, race, smoking history, and gen-
der). P values are reported as indicated.
Results
Patient and Specimen Characteristics
The demographic and clinical characteristics of the 234
patients included in this study are listed in Table I. Over-
all, 38% of the patients were male and 62% were female.
Smoking history was available in 217 (93%) patients;
racial and ethnic data were available in 186 (80%)
patients. The distribution of gender, smoking history, and
racial/ethnic background were similar in patients for both
SP and CB specimen sets (P ¼ 0.33, P ¼ 0.34, P ¼
0.092, respectively, indicating lack of statistically signifi-
cant difference in the populations studied). The type
and site of each of the cytology specimens is listed in
Table II.
Matched Specimen Evaluation
To determine first whether a mutation could be detected
in cytology cell block material, we identified cases which
met the following criteria: (1) resection and cytology
evaluation had been performed on the same site in the
same patient, (2) cytology cell block was available, (3)
prior positive finding of mutation by directed EGFR
mutation analysis had been accomplished in the resection
material, and (4) all pathologic material was available for
testing. The evaluation was restricted to cases in which a
prior directed EGFR mutation analysis was positive, as a
negative mutation evaluation in cytology material in
which the resection was negative would not be informa-
tive. Three (3) cases in which all criteria were met were
identified, one with the L858R mutation in the resection
specimen, the other two specimens showing an exon 19
in-frame deletion of 15 base pairs in the resection speci-
men. Testing of the paired cytology specimen from the
same site demonstrated the presence of the same mutation
in all three cases (Fig. 1, one representative sample
depicted). Of note, the cytology specimen showed a low
yield of genomic DNA in one of the three cases,
(extracted DNA concentration of 0.6 ng/ul, 130 ng/ul,
25ng/ul in the three specimens); however this low input
material did not prevent detection of the mutation. Only
the specimen in Figure 1 is included in the subsequent
analysis, as evaluation of the EGFR mutation status in the
remaining two cytology specimens was not undertaken as
part of clinical routine, and was instead investigated
strictly for concordance with the known EGFR mutation
status seen in a resection specimen.
EGFR Mutation Status
As there were limited cases in which evaluation of paral-
lel surgical and resection specimens could be performed,
cytology specimens were evaluated for the rate of positive
mutation detection as a surrogate mechanism to evaluate
adequacy. Only specimens in which the clinical testing of
EGFR mutation status was performed on the cytology
specimen, typically due to lack of availability of a SP
specimen showing tumor, were included in the analysis.
Of the 42 cytology specimens evaluated, a mutation was
detected in 11 (26.2%) while the mutation detection rate
for all specimens was 17.9% (42 of 234); and for surgical
specimens was 16.1% (31 of 192) (Table III). The muta-
tion detection rates between the surgical specimens and
cytology specimens are not statistically different (P ¼
0.124).
Specimen Features
To determine whether specific features of cytology cell
block specimens contribute to adequacy for mutational
analysis, the specimens were evaluated with regards to
several parameters: approximate tumor percentage, esti-
mated total specimen size, number of 10-cell clusters/310
field, and DNA concentration (Table IV). Based on a
minimum specimen DNA concentration of 25 ng/ul (the
specimen DNA concentration for which the assay was
Fig. 1. Electropherograms of matched resection and cytology patient
specimen for EGFR L858R mutation. Arrow indicates the peak gener-
ated from Sau96I digestion of mutant PCR product. A: Resection speci-
men; (B) cytology cell block; (C) positive control; (D) negative control.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
Table III. Mutation Frequencies by Specimen Type
All Cases Surgical cases Cytology cases
N 234 192 42
No. Positive (%) 42 (17.9) 31 (16.1) 11 (26.2)
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validated), 29 (69.0%) of 42 cell block specimens would
have been classified as inadequate based on DNA concen-
tration. However, of these 29 specimens, 10 had detectable
mutation, representing about 91% of all cytology specimens
with a detectable mutation and 15 (51.7% of total) of the 29
low yield specimens had DNA concentration that were less
than 25% of the ideal input; yet 5 of these had a detectable
mutation. The lowest DNA concentration with which a
mutation was detectable was 0.6 ng/ul (case no. 1), which
is more than 30-fold less than the ideal input for the assay.
Of the 11 cell block specimens with an identifiable
mutation, all were estimated to have at least 10% tumor
cellularity. This targeted mutation assay was previously
determined to have an analytic sensitivity of *5% based
on dilution studies; thus it would be expected that in a
population heterozygous for mutation without concurrent
gene amplification, 10% tumor cellularity would represent
the limit of detection. Of the 42 cell block specimens
evaluated, 7 demonstrated less than 10% tumor cellular-
ity, and all of these were negative for detectable mutation.
Additionally, the utilization of concurrent immunohisto-
chemistry in evaluation of cell block specimens was felt
to be of significant interpretive benefit in pre-testing eval-
uation of the specimens, as they often highlighted isolated
tumor cells.
Evaluation of cytology specimen size and number of
10-cell clusters per 310 field demonstrated that 9 had
low number of 10-cell clusters per 310 field (1–3 clus-
ters/310 field), and of these 9 specimens, 5 (55.5%) also
had low tumor cellularity. All cases with a low number of
10-cell clusters per 310 field were negative for detectable
mutation. Two specimens could not be evaluated for num-
ber of 10-cell clusters per 310 field as the slides were
not available at the time of analysis of cell clusters. Of
Table IV. Cell Block Evaluation
Case no. Tumor percentage (%) TTF-1 IHC 103 clusters Specimen size DNA concentration (ug/uL) Mutation status
1 >10–25 Y 4–6 0.5–2 mm2 0.6 L858R
2 >25–50 Y 4–6 0.5–2 mm2 1.7 L858R
3 >50 N >7 2–5 mm2 139 WT
4 >50 Y >7 2–5 mm2 254 Exon 19 deletion
5 >50 Y >7 2–5 mm2 79 WT
6 >25–50 Y 4–6 0.5–2 mm2 0.8 L858R
7 <5 N 1–3 Scant 8 WTa
8 >5–10 N 4–6 2–5 mm2 28 WT
9 >25–50 N >7 >5 mm2–1 cm2 4 WT
10 >10–25 N 4–6 0.5–2 mm2 6 WT
11 >50 N >7 >5 mm2–1 cm2 37 WT
12 >10–25 Y >7 0.5–2 mm2 2 Exon 19 deletion
13 >25–50 N 4–6 0.5–2 mm2 6 WT
14 >10–25 Y >7 2–5 mm2 9 WT
15 >25–50 Y >7 >5 mm2–1 cm2 14 Exon 19 deletion
16 >10–25 Y N/Aa Scant 2 WT
17 <5 N 1–3 0.5–2 mm2 3 WT
18 >25–50 N >7 2–5 mm2 34 Exon 19 deletion
19 <5 Y N/Aa 2–5 mm2 8 WT
20 >25–50 Y 4–6 0.5–2 mm2 6 WT
21 <5 N N/Aa 0.5–2 mm2 6 WT
22 >25–50 Y 1–3 0.5–2 mm2 0 WT
23 >5–10 Y 1–3 0.5–2 mm2 28 WT
24 >50 N >7 >5 mm2–1 cm2 33 WT
25 >10–25 N 1–3 Scant 5 WT
26 >25–50 Y 1–3 Scant 17 WT
27 >50 Y >7 >5 mm2–1 cm2 85 WT
28 >50 Y 4–6 0.5–2 mm2 19 Exon 19 deletion
29 >25–50 Y 4–6 0.5–2 mm2 38 WT
30 >25–50 N 1–3 0.5–2 mm2 14 WT
31 >25–50 Y 1–3 0.5–2 mm2 18 WT
32 >50 N >7 2–5 mm2 23 WT
33 >50 Y >7 0.5–2 mm2 23 WT
34 >50 N >7 0.5–2 mm2 14 L858R
35 >50 Y 4–6 2–5 mm2 20 L858R
36 >50 N >7 2–5 mm2 17 WT
37 >50 N >7 0.5–2 mm2 35 WT
38 >50 Y >7 2–5 mm2 35 WT
39 >25–50 N >7 0.5–2 mm2 14 WT
40 >5–10 Y 1–3 Scant 1 WT
41 >50 Y 4–6 scant 4 L858R
42 >50 N >7 2–5 mm2 60 WT
aSlides not available for review of this feature.
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the 11 specimens positive for mutation, 8 (72.7%) showed
an estimated total specimen size of 0.5–2 mm2. There
was a trend towards correlation between DNA yield and
visually estimated size of specimen, with larger specimens
tending to have higher DNA yields (not evaluated statisti-
cally), however of the 29 specimens with low DNA
yields, 7 were from specimens of size >2 mm2. Addition-
ally, there was trend of low number of 10-cell clusters/
310 field with low DNA yields, with 8 of 9 such speci-
mens showing low yields.
Of the 42 cell block specimens evaluated, 25 (59.5%)
had a size of <2 mm2. Twenty of these specimens dem-
onstrated tumor cellularity of >10%, and 15 demonstrated
tumor cellularity of >25%. Overall, 29 (69.0%) of all
specimens had a tumor cellularity of >25%. An example
of a specimen with low specimen size with high tumor
cellularity is shown in Figure 2.
Discussion
Evaluation of mutation status in NSCLC is becoming
increasingly important, as therapeutic options rest on the
genotypic characterization of the tumor. Recent large clin-
ical trials have conclusively demonstrated the benefit of
EGFR tyrosine kinase inhibitor therapy, and have further
demonstrated the association of response with the pres-
ence of mutation in EGFR.6,12 However, as patients fre-
quently present with advanced disease, it is common for
the initial diagnosis to be established using cytopathology,
with no intention for surgical resection of the primary
lesion. In this setting, it is critical to use existing material
from cytologic specimens to genotypically characterize the
lesion for potential beneficial therapeutic options. Several
studies have demonstrated that extremely small specimens,
such as cytology CB, can be utilized for directed EGFR
mutation analysis.10,13–23 The finding that a mutation is de-
tectable in small specimens with extremely low yield of
genomic DNA indicates that the size and/or yield of the
specimen is not necessarily a limiting factor for mutational
analysis. However, as the analytic methodology was vali-
dated using an input level of nucleic acid that is above the
yield for many small specimens, for those specimens which
did not meet this input requirement and had a negative
result, we have routinely included a disclaimer in the mo-
lecular pathology report to indicate that the analytic sensi-
tivity of the assay may be compromised by reduced nucleic
acid input. Additionally, it is critical to anticipate that in
the era of ‘‘personalized medicine,’’ as the number of ana-
lytes routinely requested per specimen rises, our ability to
comprehensively accommodate such requests may be lim-
ited. Therefore it is critical to either design a test which
simultaneously evaluates multiple analytes using small
quantities of input material, or recognize that clinical pri-
oritization of testing is likely to be necessary.
In this study, all specimens which had a detectable
mutation showed a tumor cellularity of at least 10%,
which is concordant with the analytic sensitivity of the
Fig. 2. Representative example of cytology cell block specimen with small size, low overall cellularity, and high tumor cellularity (A) scanning power
(33); (B) 703 (inset box); (C) 1003 (inset box). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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method utilized. Though based on our limited cohort it is
not possible to definitively conclude that 10% tumor cel-
lularity is the requirement for specimen adequacy using
this testing methodology, our data strongly suggest this is
the case. It is important to note that this pre-analytic eval-
uation is dependent on the methodology utilized for pre-
analytic processing and mutation analysis. Utilization of a
different methodology, such as Sanger sequencing, would
likely require that a greater proportion of tumor be present to
confidently detect mutation, or lack thereof. Similarly, a
change in pre-analytic processing (such as microdissection
in which tumor cells are selectively isolated microscopically,
either through manual microdissection, or laser capture
microdissection) could impact the threshold which is used to
judge the suitability of specimens for testing. Although a
side-by-side evaluation of different pre-analytic processing
or mutation detection methodologies was not attempted in
this study, knowledge of the analytic sensitivity of the spe-
cific assay methodology performed by a testing laboratory is
key in establishing criteria for acceptability of specimens.
This also underscores the necessity for morphologic evalua-
tion of specimens which are tested for EGFR mutation, as
testing a specimen without such evaluation may result in a
false negative due to low tumor cellularity in a specimen.
Immunohistochemical stains such as TTF-1 can help to con-
firm a morphologic impression of tumor cell content in a
specimen; however, caution must be exercised to not over
interpret staining of normal or reactive cells within the speci-
men. This approach was found by these authors to be espe-
cially useful in the setting of specimens from anatomic loca-
tions in which staining of background cells would not be
anticipated (i.e., lymph node aspirate).
These findings are consistent with previous studies
which have demonstrated that EGFR mutations can be
detected utilizing a variety of methodologies on cytopa-
thologic specimens, such as those obtained from endo-
bronchial ultrasound guided fine-needle aspiration (EBUS-
FNA) or other aspiration or exfoliative cytology techni-
ques.10,13–23 These data further this observation by dem-
onstrating that EGFR mutation testing can be accommo-
dated as part of the routine evaluation of specimens from
patients with NSCLC.
One potential confounding factor in this approach to
EGFR mutational analysis is the potential for misleading
results due to tumor heterogeneity or discordance between
primary and metastasis. As cytopathology specimens rep-
resent a small sampling of a larger lesion, a negative
result may reflect sampling bias. Similarly, data suggest
that the EGFR mutation status may be discordant between
primary and metastasis in a proportion of cases; thus eval-
uation of a cytopathology specimen from a primary may
not reflect the status of a metastasis, or vice versa.24,25 In
addition, given the observation that 40–50% of NSCLC
harbor EGFR copy number gains,26–28 the possibility that
some of the evaluated specimens have concurrent EGFR
amplification may also account for the successful detec-
tion of mutation in a subset of patients. Analysis for
EGFR amplification was not performed in this study to
determine the relationship between successful mutation
detection and gene copy number.
As EGFR mutation testing becomes more common,
additional options are likely to be available and useful in
the evaluation of small specimens, especially cytopatho-
logic preparations. One option for this evaluation includes
the direct testing of cytopathology smears. A recent study
demonstrated the feasibility of using material directly
from smeared slides for genomic DNA based applications,
with some slides having been archived for many years,
and in which the quality of the extracted nucleic acid is
high.29 Several protocols in which tumor cells are selec-
tively dissected from a cytology smear are available,30,31
and this approach may provide an avenue for testing in
patients in whom a cell block preparation was not gener-
ated as part of the cytopathology work-up. This novel
approach is likely to have applications in clinical practice,
especially in the setting of cases in which there is insuffi-
cient material for both smear and cell block preparation.
However, there are obstacles which may limit widespread
adoption of this methodology. One major obstacle is the
need to ‘‘sacrifice’’ a smeared slide for this approach,
which has potential ramifications in future consultation
review of pathology material, and requires a clear under-
standing of the policies which could allow for such utili-
zation. Additionally, as a novel approach for acquiring a
substrate for molecular testing, laboratories must validate
this methodology to accept specimens in this manner,
which requires time and resources to complete. In conclu-
sion, cytopathology CB are frequently adequate for EGFR
mutation testing, and present a viable option for obtaining
this important information in advanced stage NSCLC
patients. Evaluation of the cytology specimen should be
paired with knowledge of the mutation testing methodol-
ogy, and tumor enrichment methods to allow for assess-
ment of sample adequacy for testing.
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